

# Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

#### Published on 11/12/2020

COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

## Pathogen and Human Genomics Studies

 Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=335) AC Walls et al, Cell, October 31, 2020

Two-component nanoparticle platform enabled rapid generation of SARS-CoV-2 vaccines. The RBD-nanoparticle vaccines elicit potent neutralizing antibody responses. Nanoparticle vaccineelicited antibodies target multiple non-overlapping epitopes. • The lead nanoparticle vaccine candidate is being manufactured for clinical trials.

 Wastewater Analysis of SARS-CoV-2 as a Predictive Metric of Positivity Rate for a Major Metropolis (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=343)
LB Stadler et al, MEDRXIV, November 6, 2020

We report wastewater viral RNA levels of SARS-CoV-2 in a major metropolis serving over 3.6 million people geographically spread over 39 distinct sampling sites. Viral RNA levels were followed weekly for 22 weeks, both before, during, and after a major surge in cases, and simultaneously by two independent laboratories. We found SARS-CoV-2 RNA wastewater levels were a strong predictive indicator of trends in the nasal positivity rate two-weeks in advance.

 COVID-19 Wastewater Epidemiology: A Model to Estimate Infected Populations (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=346) CS MacMahan et al, MEDRXIV, November 7, 2020

Composite wastewater samples were collected from three sewersheds and tested for SARS-CoV-2 RNA. A Susceptible-Exposed-Infectious-Removed (SEIR) model based on mass rate of SARS-CoV-2 RNA in the wastewater was developed to predict the number of infected individuals. Predictions were compared to confirmed cases identified by the South Carolina Department of Health and Environmental Control for the same time period and geographic area.

 Pooled testing for SARS-CoV-2 could provide the solution to UK's testing strategy (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=352) J Ball et al, BMJ, November 9, 2020

Pooled sampling of what is essentially asymptomatic swabs would allow rolling surveillance programmes in schools, care homes, universities and colleges, and high risk factory settings without having a major impact on the daily covid-19 test capacity.

 Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=357) Roy Chayan et al. Genomics 2020 Nov

Phylogeny of 4618 spatiotemporally-representative genomes revealed that entities belonging to the early lineages are mostly spread over Asian countries, including India, whereas the recentlyderived lineages are more globally distributed. Of the total 20,163 instances of polymorphism detected across global genomes, 12,594 and 7569 involved transitions and transversions, predominated by cytidine-to-uridine and guanosine-to-uridine conversions, respectively.

## Non-Genomics Precision Health Studies

 Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=335) AC Walls et al, Cell, October 31, 2020

Two-component nanoparticle platform enabled rapid generation of SARS-CoV-2 vaccines. The RBD-nanoparticle vaccines elicit potent neutralizing antibody responses. Nanoparticle vaccineelicited antibodies target multiple non-overlapping epitopes. • The lead nanoparticle vaccine candidate is being manufactured for clinical trials.

 Wastewater Analysis of SARS-CoV-2 as a Predictive Metric of Positivity Rate for a Major Metropolis (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=343)
LB Stadler et al, MEDRXIV, November 6, 2020

We report wastewater viral RNA levels of SARS-CoV-2 in a major metropolis serving over 3.6 million people geographically spread over 39 distinct sampling sites. Viral RNA levels were followed weekly for 22 weeks, both before, during, and after a major surge in cases, and simultaneously by two independent laboratories. We found SARS-CoV-2 RNA wastewater levels were a strong predictive indicator of trends in the nasal positivity rate two-weeks in advance.

 COVID-19 Wastewater Epidemiology: A Model to Estimate Infected Populations (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=346) CS MacMahan et al, MEDRXIV, November 7, 2020

Composite wastewater samples were collected from three sewersheds and tested for SARS-CoV-2 RNA. A Susceptible-Exposed-Infectious-Removed (SEIR) model based on mass rate of SARS-CoV-2 RNA in the wastewater was developed to predict the number of infected individuals. Predictions were compared to confirmed cases identified by the South Carolina Department of Health and Environmental Control for the same time period and geographic area.

 Pooled testing for SARS-CoV-2 could provide the solution to UK's testing strategy (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=352)
J Ball et al, BMJ, November 9, 2020

Pooled sampling of what is essentially asymptomatic swabs would allow rolling surveillance

programmes in schools, care homes, universities and colleges, and high risk factory settings without having a major impact on the daily covid-19 test capacity.

Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=357) Roy Chayan et al. Genomics 2020 Nov

Phylogeny of 4618 spatiotemporally-representative genomes revealed that entities belonging to the early lineages are mostly spread over Asian countries, including India, whereas the recentlyderived lineages are more globally distributed. Of the total 20,163 instances of polymorphism detected across global genomes, 12,594 and 7569 involved transitions and transversions, predominated by cytidine-to-uridine and guanosine-to-uridine conversions, respectively.

### News, Reviews and Commentaries

 Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=335)
AC Walls et al, Cell, October 31, 2020

Two-component nanoparticle platform enabled rapid generation of SARS-CoV-2 vaccines. The RBD-nanoparticle vaccines elicit potent neutralizing antibody responses. Nanoparticle vaccine elicited antibodies target multiple non-overlapping epitopes. • The lead nanoparticle vaccine candidate is being manufactured for clinical trials.

Wastewater Analysis of SARS-CoV-2 as a Predictive Metric of Positivity Rate for a Major Metropolis (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=343)

LB Stadler et al, MEDRXIV, November 6, 2020

We report wastewater viral RNA levels of SARS-CoV-2 in a major metropolis serving over 3.6 million people geographically spread over 39 distinct sampling sites. Viral RNA levels were followed weekly for 22 weeks, both before, during, and after a major surge in cases, and simultaneously by two independent laboratories. We found SARS-CoV-2 RNA wastewater levels were a strong predictive indicator of trends in the nasal positivity rate two-weeks in advance.

• COVID-19 Wastewater Epidemiology: A Model to Estimate Infected Populations (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=346) CS MacMahan et al, MEDRXIV, November 7, 2020

Composite wastewater samples were collected from three sewersheds and tested for SARS-CoV-2 RNA. A Susceptible-Exposed-Infectious-Removed (SEIR) model based on mass rate of SARS-CoV-2 RNA in the wastewater was developed to predict the number of infected individuals. Predictions were compared to confirmed cases identified by the South Carolina Department of Health and Environmental Control for the same time period and geographic area.

 Pooled testing for SARS-CoV-2 could provide the solution to UK's testing strategy (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=352)
J Ball et al, BMJ, November 9, 2020

Pooled sampling of what is essentially asymptomatic swabs would allow rolling surveillance programmes in schools, care homes, universities and colleges, and high risk factory settings without having a major impact on the daily covid-19 test capacity.

 Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=357) Roy Chayan et al. Genomics 2020 Nov

Phylogeny of 4618 spatiotemporally-representative genomes revealed that entities belonging to the early lineages are mostly spread over Asian countries, including India, whereas the recentlyderived lineages are more globally distributed. Of the total 20,163 instances of polymorphism detected across global genomes, 12,594 and 7569 involved transitions and transversions, predominated by cytidine-to-uridine and guanosine-to-uridine conversions, respectively.

**Disclaimer**: Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

Page last reviewed: Oct 1, 2020

Page last updated: Jan 19, 2021

Content source: Office of Genomics and Precision Public Health (http://www.cdc.gov/genomics/), CDC Office of Science

(https://www.cdc.gov/od/science/index.htm)